Orthocell Limited (OCC.AX)
AUD 1.58
(-1.25%)
AUD 1.58
(-1.25%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 | 3.68 Million AUD | 20.51% |
| 2023 | 3.06 Million AUD | 267.65% |
| 2022 | 832.51 Thousand AUD | 177.62% |
| 2021 | 299.88 Thousand AUD | 4786.37% |
| 2020 | -6399.00 AUD | -103.0% |
| 2019 | 213.32 Thousand AUD | 42.89% |
| 2018 | 149.29 Thousand AUD | 62.84% |
| 2017 | 91.68 Thousand AUD | -45.72% |
| 2016 | 168.91 Thousand AUD | 22.78% |
| 2015 | 137.57 Thousand AUD | 45.96% |
| 2014 | 94.25 Thousand AUD | 123.82% |
| 2013 | 42.11 Thousand AUD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 FY | 3.65 Million AUD | 19.46% |
| 2024 Q2 | 1.79 Million AUD | 0.0% |
| 2024 Q4 | 3.08 Million AUD | 0.0% |
| 2023 FY | 3.06 Million AUD | 267.65% |
| 2023 Q2 | 335.5 Thousand AUD | 0.0% |
| 2023 Q4 | 2.72 Million AUD | 0.0% |
| 2022 Q2 | 242.33 Thousand AUD | 0.0% |
| 2022 Q4 | 590.18 Thousand AUD | 0.0% |
| 2022 FY | 832.51 Thousand AUD | 177.62% |
| 2021 FY | 299.88 Thousand AUD | 4786.37% |
| 2021 Q4 | 192.48 Thousand AUD | 0.0% |
| 2021 Q2 | 107.39 Thousand AUD | 0.0% |
| 2020 FY | -6399.00 AUD | -103.0% |
| 2020 Q4 | -117.8 Thousand AUD | 0.0% |
| 2020 Q2 | 111.41 Thousand AUD | 0.0% |
| 2019 FY | 213.32 Thousand AUD | 42.89% |
| 2019 Q4 | 48.59 Thousand AUD | 0.0% |
| 2019 Q2 | 164.72 Thousand AUD | 0.0% |
| 2018 Q2 | 63.78 Thousand AUD | 0.0% |
| 2018 FY | 149.29 Thousand AUD | 62.84% |
| 2018 Q4 | 85.5 Thousand AUD | 0.0% |
| 2017 FY | 91.68 Thousand AUD | -45.72% |
| 2017 Q2 | 63.22 Thousand AUD | 0.0% |
| 2017 Q4 | 28.45 Thousand AUD | 0.0% |
| 2016 Q2 | 115.14 Thousand AUD | 0.0% |
| 2016 Q4 | 53.76 Thousand AUD | 0.0% |
| 2016 FY | 168.91 Thousand AUD | 22.78% |
| 2015 Q2 | 62 Thousand AUD | 0.0% |
| 2015 Q4 | 75.56 Thousand AUD | 0.0% |
| 2015 FY | 137.57 Thousand AUD | 45.96% |
| 2014 FY | 94.25 Thousand AUD | 123.82% |
| 2014 Q4 | 43.26 Thousand AUD | 0.0% |
| 2014 Q2 | 50.98 Thousand AUD | 0.0% |
| 2013 FY | 42.11 Thousand AUD | 0.0% |
| 2013 Q3 | - AUD | -100.0% |
| 2013 Q4 | -17.01 Thousand AUD | 0.0% |
| 2013 Q2 | 59.12 Thousand AUD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| AdAlta Limited | 1.5 Million AUD | -144.604% |
| Acrux Limited | -1.28 Million AUD | 387.26% |
| Actinogen Medical Limited | 9.93 Million AUD | 62.861% |
| AnteoTech Limited | 460.39 Thousand AUD | -701.139% |
| Argenica Therapeutics Limited | 2.59 Million AUD | -41.975% |
| Arovella Therapeutics Limited | -25.97 Thousand AUD | 14297.706% |
| Anatara Lifesciences Ltd | -748.91 Thousand AUD | 592.505% |
| Alterity Therapeutics Limited | 3.8 Million AUD | 3.063% |
| Amplia Therapeutics Limited | 4.01 Million AUD | 8.037% |
| Avecho Biotechnology Limited | -43.79 Thousand AUD | 8522.016% |
| Bio-Gene Technology Limited | -301.44 Thousand AUD | 1323.564% |
| Biome Australia Limited | 7.66 Million AUD | 51.909% |
| Biotron Limited | -40.49 Thousand AUD | 9207.665% |
| Botanix Pharmaceuticals Limited | -6.55 Million AUD | 156.299% |
| BTC Health Limited | 16.36 Thousand AUD | -22445.367% |
| Chimeric Therapeutics Limited | 7.45 Million AUD | 50.516% |
| CSL Limited | 15.28 Billion AUD | 99.976% |
| Clarity Pharmaceuticals Ltd | 11.5 Million AUD | 67.945% |
| Clinuvel Pharmaceuticals Limited | 78.09 Million AUD | 95.277% |
| Cynata Therapeutics Limited | 2.31 Million AUD | -59.283% |
| Dimerix Limited | 583.47 Thousand AUD | -532.144% |
| EZZ Life Science Holdings Limited | 50.94 Million AUD | 92.76% |
| Hexima Limited | - AUD | -Infinity% |
| Island Pharmaceuticals Limited | 1.25 Million AUD | -194.702% |
| Immuron Limited | 3.33 Million AUD | -10.538% |
| Immutep Limited | 1.44 Million AUD | -155.448% |
| Imugene Limited | -5.83 Million AUD | 163.16% |
| Invex Therapeutics Ltd | 1.21 Million AUD | -204.261% |
| Memphasys Limited | 1606.00 AUD | -229565.131% |
| Nanollose Limited | -348.95 Thousand AUD | 1157.0% |
| Neuren Pharmaceuticals Limited | 205.17 Million AUD | 98.202% |
| Noxopharm Limited | -534.81 Thousand AUD | 789.668% |
| NeuroScientific Biopharmaceuticals Limited | -91.33 Thousand AUD | 4138.256% |
| Nyrada Inc. | -5164.07 AUD | 71524.71% |
| PharmAust Limited | -1641.00 AUD | 224866.728% |
| Patrys Limited | 1.39 Million AUD | -164.562% |
| Paradigm Biopharmaceuticals Limited | 56.81 Thousand AUD | -6392.329% |
| Proteomics International Laboratories Limited | -1.12 Million AUD | 428.388% |
| Prescient Therapeutics Limited | 3.71 Million AUD | 0.645% |
| PYC Therapeutics Limited | 22.05 Million AUD | 83.28% |
| Race Oncology Limited | 1.38 Million AUD | -165.37% |
| Radiopharm Theranostics Limited | -21.3 Million AUD | 117.31% |
| Recce Pharmaceuticals Ltd | -366.76 Thousand AUD | 1105.655% |
| Starpharma Holdings Limited | 7.65 Million AUD | 51.829% |
| Telix Pharmaceuticals Limited | 308.5 Million AUD | 98.804% |
| Tissue Repair Ltd | 150.51 Thousand AUD | -2350.6% |
| Zelira Therapeutics Limited | 10.28 Thousand AUD | -35765.636% |